Tesamorelin / Ipamorelin is a combination of a growth hormone-releasing hormone (GHRH) analog (Tesamorelin) and a growth hormone secretagogue (Ipamorelin). It is used in provider-directed therapy and should be evaluated based on the individual patient, treatment objective, and applicable prescribing information.
What It Is Used For
Tesamorelin / Ipamorelin is commonly considered in provider-directed programs focused on the following areas of interest:
Growth Hormone Pathway Support — Often considered in provider-directed programs designed to support endogenous growth hormone secretion through complementary GHRH and GHRP pathways.
Body Composition Support — May be explored within programs focused on body composition and lean-mass-related wellness goals.
Metabolic Health — May be considered for patients whose goals include support for metabolic wellness and related body-composition objectives.
Tesamorelin / Ipamorelin should be evaluated against applicable prescribing information. Information provided by ALML is intended for healthcare professionals and does not replace independent clinical judgment.
How It Works
Tesamorelin / Ipamorelin combines a growth hormone-releasing hormone (GHRH) analog (Tesamorelin) with a growth hormone secretagogue (Ipamorelin) to stimulate endogenous growth hormone secretion through two complementary pathways. Areas of biological activity include:
Areas being studied include:
GHRH Receptor Interaction — Tesamorelin binds to growth hormone-releasing hormone receptors, stimulating the release of endogenous growth hormone from the pituitary.
Ghrelin Receptor (GHSR) Interaction — Ipamorelin acts as a growth hormone secretagogue, interacting with the ghrelin receptor to further promote growth hormone release.
Complementary Secretion Pathways — The combination has been studied for its potential to support pulsatile growth hormone release through complementary stimulation of two distinct pathways.
IGF-1 and Metabolic Pathways — Increased growth hormone secretion may influence downstream pathways, including IGF-1 and related metabolic processes.
Clinical use of Tesamorelin / Ipamorelin varies by patient-specific factors and applicable prescribing information. The treating healthcare professional remains responsible for all clinical decision-making. This information is educational and does not establish clinical efficacy for any specific use.
Clinical Information
Healthcare professionals should independently evaluate the available evidence, patient-specific factors, potential risks, and applicable regulatory requirements before considering Tesamorelin / Ipamorelin for a patient.
Include these considerations:
Patient-Specific Assessment Required — Providers should consider the patient's medical history, current medications, allergies, pregnancy or breastfeeding status, and other relevant clinical factors before use.
Use Within Approved and Appropriate Context — Tesamorelin / Ipamorelin should be evaluated against applicable prescribing information and used only where clinically appropriate for the individual patient.
Monitor Tolerance and Relevant Clinical Factors — Providers should monitor patient tolerance and relevant clinical factors, including growth-hormone-related markers, throughout the course of use.
Treatment Decisions Remain With the Licensed Healthcare Professional — All treatment, prescribing, and dosing decisions remain solely the responsibility of the appropriately licensed healthcare professional.
ALML provides product and educational information for healthcare professionals. This information is not a substitute for prescribing information, pharmacy labeling, applicable law, or independent clinical judgment.
Available Options
Option 1
Verified formulations and strengths will be updated based on current pharmacy availability.
Dosing & Reconstitution
For provider use only. Calculates reconstitution math — does not select or recommend a patient dose.
Product Dosing Schedule
Provider Inputs
Calculated Outputs
Concentration
—
Medication amount ÷ diluent mL
Volume to Draw
—
Desired dose ÷ concentration
U-100 Syringe Units
—
Volume to draw × 100 — 100 syringe units = 1.00 mL · 1 syringe unit = 0.01 mL
| Low / Starting Dose | 1 mg once daily |
| Standard Dose | 1.5 mg once daily |
| High Dose | 2 mg once daily |
| Frequency | Daily |
| Dose Unit | mg/day |
| Administrations Per Week | 7 |
Dosing information is provided for healthcare-professional reference only when verified. Patient-specific dosing and prescribing decisions remain the responsibility of the treating healthcare professional. Reference dosing reflects a blend; component-specific dosing is not established. The calculator determines the actual syringe draw from the entered vial amount and diluent — no fixed vial strength is implied.
This tool performs reconstitution/administration math only. It does not select, recommend, or validate a patient dose. Dosing decisions are the responsibility of the prescribing healthcare provider.
Ask ALML
Ask ALML may identify Tesamorelin / Ipamorelin as a product for a healthcare professional to explore when the described patient goals involve growth hormone pathway support, body composition, or metabolic health.
The match is informational. Ask ALML is designed to help healthcare professionals navigate the ALML portfolio and identify potentially relevant options for further clinical consideration. It does not diagnose a patient, prescribe treatment, determine medical necessity, or select patient-specific dosing.
Submit an order request or ask about availability. A request is not a guaranteed order — every inquiry goes to ALML staff for manual review and follow-up.
ALML does not guarantee that any specific therapy can be supplied. Availability is confirmed through manual review of each request.